Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)

Kang, Sohi; Choi, Seong Hye; Lee, Byung Hwa; Jeong, Yoong Ki; Hahm, Dong Seok; Han, Il Woo; Cummings, Jeffrey L.; Na, Duk L.

doi:10.1177/089198873258818

Cited by 65 publications

(41 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The primary efficacy outcome was the change from baseline to PI in the modified AD Assessment Scale-cognitive subscale (ADAS-Cog, range 0-89) [25]. Secondary outcome measures included the MMSE (range 0-30) [17], Digit Symbol Coding test (range 0-90), Stroop test (range 0-112), Animal Fluency, Controlled Oral Word Association Test (COWAT), story recall test [20], Forward Digit Span test (range 0-9), Backward Digit Span test (range 0-8), CDR-Sum of Boxes (CDR-SB, range 0-18) [16], 15-item version of the Geriatric Depression Scale (GDS-15, range 0-15) [26], Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI, range 0-144) [27], Bayer ADL (range 1-10) [28], Prospective and Retrospective Memory Questionnaire (PRMQ, range 16-80) [29,30], AD8 (range 0-8) [31], Prospective Memory Test (PMT, range 0-12) modified from the Royal Prince Alfred PMT [32], QOL-AD (range 0-52) [33] and Multifactorial Metamemory Questionnaire (MMQ)-Strategy subscale (range 0-76) [22,34]. The PMT consisted of four tests regarding short- and long-term, and event- and time-based prospective memory.…”

Section: Methodsmentioning

confidence: 99%

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Jeong

Choi

et al. 2016

Psychother Psychosom

Self Cite

View full text Add to dashboard Cite

Background: We examined the efficacy of group-based cognitive intervention (GCI) and home-based cognitive intervention (HCI) in amnestic mild cognitive impairment (aMCI) and intervention effects on serum brain-derived neurotrophic factor (BDNF). Methods: In this randomized and rater-blinded trial, 293 patients with aMCI from 18 nationwide hospitals were randomized: 96 to the GCI group, 98 to the HCI group and 99 to the control group. For 12 weeks, subjects receiving GCI participated twice per week in group sessions led by trained instructors, and those receiving HCI completed homework materials 5 days per week. They were assessed at baseline, postintervention (PI) and at the 6-month follow-up after the intervention. The primary endpoint was the change from baseline to PI in the modified Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog). Results: In comparison to the controls (a 0.8-point decrease), the subjects receiving GCI (a 2.3-point decrease, p = 0.01) or HCI (a 2.5-point decrease, p = 0.02) showed significant improvements in the modified ADAS-Cog at PI, respectively. By the 6-month follow-up, those receiving GCI or HCI had better scores in the modified ADAS-Cog than the controls. The changes in BDNF levels significantly correlated with the changes in the modified ADAS-Cog in the GCI (r = -0.29, p = 0.02 at PI) and HCI (r = -0.27, p = 0.03 at 6-month follow-up) groups, respectively. Conclusions: The GCI and HCI resulted in cognitive improvements in aMCI. An enhanced brain plasticity may be a component of the mechanism underpinning the cognitive improvements associated with the cognitive interventions.

show abstract

Section: Methodsmentioning

confidence: 99%

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Jeong

Choi

et al. 2016

Psychother Psychosom

Self Cite

View full text Add to dashboard Cite

show abstract

“…The supplementary clinical outcomes were estimated with the MMSE, Frontal Assessment Battery (FAB) [16], caregiver-administered Neuropsychiatric Inventory (CGA-NPI) [17], and Alzheimer's Disease Cooperative Study-Activities of Daily Living inventory (ADCS-ADL) [18]. The MMSE was administered at screening, baseline, and at the end of the study.…”

Section: Methodsmentioning

confidence: 99%

Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease

et al. 2014

Self Cite

View full text Add to dashboard Cite

Background: The K variant of butyrylcholinesterase (BCHE-K) exhibits a reduced acetylcholine-hydrolyzing capacity; so the clinical response to rivastigmine may differ in Alzheimer's disease (AD) patients with the BCHE-K gene. Objective: To investigate the clinical response to rivastigmine transdermal patch monotherapy or memantine plus rivastigmine transdermal patch therapy in AD patients based on the BCHE-K gene. Methods: A total of 146 probable AD patients consented to genetic testing for butyrylcholinesterase and underwent the final efficacy evaluations. Responders were defined as patients with an equal or better score on the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) at 16 weeks compared to their baseline score. Results:BCHE-K carriers showed a lower responder rate on the ADAS-cog than non-carriers (38.2 vs. 61.7%, p = 0.02), and this trend was evident in AD patients with apolipoprotein E I 4 (35 vs. 60.7%, p = 0.001). The presence of the BCHE-K allele predicted a worse response on the ADAS-cog (odds ratio 0.35, 95% confidence interval 0.14-0.87), after adjusting for demographic and baseline cognitive and functional variables. Conclusion: The BCHE-K genotype may be related to a poor cognitive response to rivastigmine patch or memantine add-on therapy, especially in the presence of apolipoprotein E I 4. i 2014 S. Karger AG, Basel

show abstract

“…It is a semistructured instrument administered to the caregiver [14,15]. The 12 domains cover delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, euphoria/elation, apathy/indifference, disinhibition, irritability/lability, aberrant motor behavior, sleep disturbance and appetite disturbance.…”

Section: Neuropsychiatric Inventorymentioning

confidence: 99%

Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimers Disease Spectrum Using 3-Tesla MR Spectroscopy

Lim

Hong²,

Lee³

et al. 2012

Dement Geriatr Cogn Disord

View full text Add to dashboard Cite

Aims: In order to evaluate the metabolite changes of both anterior and posterior cingulate gyri during the progression of Alzheimer’s disease (AD) pathology, a 3-tesla MR spectroscopy study was performed. Methods: Thirty-six patients with AD, 19 patients with amnestic mild cognitive impairment (aMCI), and 23 cognitively normal (CN) subjects were recruited. MR spectroscopy was conducted within the anterior and posterior cingulate gyri. A one-way analysis of co-variance was used to compare the metabolite ratios of each group and correlation analysis was used to show the correlation between the metabolite ratios with the Mini-Mental State Examination (MMSE) and Neuropsychiatric Inventory (NPI). Results: The N-acetylaspartate/creatine (NAA/Cr) of the posterior cingulate gyrus was significantly higher in CN subjects than in aMCI and AD patients. On the other hand, the myoinositol/creatine (ml/Cr) of the anterior cingulate gyrus was significantly higher in AD patients than in CN subjects and aMCI patients. The ml/Cr of the posterior cingulate gyrus correlated with the MMSE and that of the anterior cingulate gyrus correlated with the NPI. Conclusion: Both the decreased NAA/Cr of the posterior cingulate gyrus and the increased ml/Cr of the anterior cingulate gyrus may reflect biochemical changes in AD according to the posterior-dominant progression of AD pathology.

show abstract

Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)

Cited by 65 publications

References 17 publications

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease

Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimers Disease Spectrum Using 3-Tesla MR Spectroscopy

Contact Info

Product

Resources

About

Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI)

Cited by 65 publications

References 17 publications

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Group- and Home-Based Cognitive Intervention for Patients with Mild Cognitive Impairment: A Randomized Controlled Trial

Effect of Rivastigmine or Memantine Add-on Therapy Is Affected by Butyrylcholinesterase Genotype in Patients with Probable Alzheimer's Disease

Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimers Disease Spectrum Using 3-Tesla MR Spectroscopy

Contact Info

Product

Resources

About

Metabolite Investigation in Both Anterior and Posterior Cingulate Gyri in Alzheimers Disease Spectrum Using 3-Tesla MR Spectroscopy